Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Jiang, Cheng ^a   Guo, Junming ^a,b   Wang, Zhe ^a   Xiao, Bingxiu ^a,b   Lee, Hyo Jung ^c   Lee, Eun Ok ^c   Kim, Sung Hoon ^c   Lu, Junxuan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NINGBO UNIVERSITY   (China)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CASPASE; DECURSIN; DECURSINOL; DECURSINOL ANGELATE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MESSENGER RNA; PYRANOCOUMARIN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOPYRAN DERIVATIVE; BUTYRIC ACID DERIVATIVE; CDKN1B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN KINASE C; SIGNAL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; HUMAN; HUMAN CELL; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; BREAST TUMOR; CELL CYCLE; CELL NUCLEUS; CYTOSOL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; METABOLISM; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; BREAST NEOPLASMS; BUTYRIC ACIDS; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 40349114562     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1790     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130.
2. Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA. 1995, 92: 3650-3657 10.1073/pnas.92.9.3650.
3. Nilsson S, Gustafsson JA: Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol. 2002, 37: 1-28 10.1080/10409230290771438.
4. Russo J, Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006, 102: 89-96 10.1016/j.jsbmb.2006.09.004.
5. Gustafsson JA: Estrogen receptor beta - a new dimension in estrogen mechanism of action. J Endocrinol. 1999, 163: 379-383 10.1677/joe.0.1630379.
6. Gustafsson JA, Warner M: Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol. 2000, 74: 245-248 10.1016/S0960-0760(00)00130-8.
7. Katzenellenbogen BS, Katzenellenbogen JA: Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000, 2: 335-344 10.1186/bcr78.
8. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001, 142: 4120-4130 10.1210/en.142.9.4120.
9. Dickson RB, Stancel GM: Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 2000, 27: 135-145.
10. Jordan VC: Third annual William L. McGuire Memorial Lecture. 'Studies on the estrogen receptor in breast cancer' - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat. 1995, 36: 267-285 10.1007/BF00713399.
11. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994, 86: 527-537 10.1093/jnci/86.7.527.
12. Jordan VC, Gapstur S, Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst. 2001, 93: 1449-1457 10.1093/jnci/93.19.1449.
13. Sporn MB, Dowsett SA, Mershon J, Bryant HU: Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther. 2004, 26: 830-840 10.1016/S0149-2918(04)90127-0.
14. Gradishar WJ: Tamoxifen - what next?. Oncologist. 2004, 9: 378-384 10.1634/theoncologist.9-4-378.
15. Howell A: Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer. 2006, 13: 689-706 10.1677/erc.1.00846.
16. Sarker SD, Nahar L: Natural medicine: the genus Angelica. Curr Med Chem. 2004, 11: 1479-1500.
17. Konoshima M, Chi HJ, Hata K: Coumarins from the root of Angelica gigas Nakai. Chem Pharm Bull. 1968, 16: 1139-1140.
18. Chi HJ, Kim HS: Studies on the components of Umbelliferae plants in Korea: pharmacological study of decursin, decursinol and nodakenin. Kor J Pharmacol. 1970, 1: 25-32.
19. Ahn KS, Sim WS, Kim IH: Decursin: a cytotoxic agent and protein kinase C activator from the root of Angelica gigas. Planta Med. 1996, 62: 7-9 10.1055/s-2006-957785.
20. Ahn KS, Sim WS, Lee IK, Seu YB, Kim IH: Decursinol angelate: a cytotoxic and protein kinase C activating agent from the root of Angelica gigas. Planta Med. 1997, 63: 360-361 10.1055/s-2006-957701.
21. Kim HH, Ahn KS, Han H, Choung SY, Choi SY, Kim IH: Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells. Leuk Res. 2005, 29: 1407-1413 10.1016/j.leukres.2005.05.001.
22. Kim HH, Sik Bang S, Seok Choi J, Han H, Kim IH: Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett. 2005, 223: 191-201 10.1016/j.canlet.2004.10.025.
23. Lee S, Shin DS, Kim JS, Oh KB, Kang SS: Antibacterial coumarins from Angelica gigas roots. Arch Pharm Res. 2003, 26: 449-452.
24. Choi SS, Han KJ, Lee HK, Han EJ, Suh HW: Antinociceptive profiles of crude extract from roots of Angelica gigas NAKAI in various pain models. Biol Pharm Bull. 2003, 26: 1283-1288 10.1248/bpb.26.1283.
25. Yan JJ, Kim DH, Moon YS, Jung JS, Ahn EM, Baek NI, Song DK: Protection against beta-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2004, 28: 25-30 10.1016/S0278-5846(03)00168-4.
26. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee JH, Kim MS, Kim SH, et al: Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006, 66: 453-463 10.1158/0008-5472.CAN-05-1865.
27. Guo J, Jiang C, Wang Z, Lee HJ, Hu H, Malewicz B, Lee HJ, Lee JH, Baek NI, Jeong JH, et al: A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer Ther. 2007, 6: 907-917 10.1158/1535-7163.MCT-06-0231.
28. 1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005, 65: 1035-1044 10.1158/0008-5472.CAN-04-1740.
29. Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS: Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res. 2003, 26: 727-730.
30. Howell A: Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit Rev Oncol Hematol. 2006, 57: 265-273 10.1016/j.critrevonc.2005.08.001.
31. Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975, 66: 188-193 10.1083/jcb.66.1.188.
32. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, Onate SA, Gao AC: Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res. 2005, 65: 3487-3492.
33. Janicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998, 273: 9357-9360 10.1074/jbc.273.16.9357.
34. 2 cell cycle arrest. Cancer Res. 2004, 64: 423-428 10.1158/0008-5472.CAN-03-2446.
35. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004, 101: 1566-1571 10.1073/pnas.0308319100.
36. Wakeling AE, Bowler J: ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol. 1992, 43: 173-177 10.1016/0960-0760(92)90204-V.
37. Robertson JF: Faslodex (ICI 182, 780), a novel estrogen receptor downregulator - future possibilities in breast cancer. J Steroid Biochem Mol Biol. 2001, 79: 209-212 10.1016/S0960-0760(01)00138-8.
38. England GM, Jordan VC: Pure antiestrogens as a new therapy for breast cancer. Oncol Res. 1997, 9: 397-402.
39. Stack G, Kumar V, Green S, Ponglikitmongkol M, Berry M, Rio MC, Nunez AM, Roberts M, Koehl C, Bellocq P, et al: Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treat Res. 1988, 40: 185-206.
40. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66: 11207-11213 10.1158/0008-5472.CAN-06-0017.